6,8-diiodocoumarin-3-carboxylic acid | 98994-72-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 6,8-diiodocoumarin-3-carboxylic acid
• 英文别名: 6,8-diiodo-2-oxo-2H-chromene-3-carboxylic acid；UBP658；6,8-diICcaH；6,8-Dijod-2-oxo-2H-chromen-3-carbonsaeure；6,8-diiodo-2-oxochromene-3-carboxylic acid
• CAS: 98994-72-0
• 化学式: C₁₀H₄I₂O₄
• 分子量: 441.948
• InChiKey: CMBVBZQPXISBGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6,8-diiodocoumarin-3-carboxylic acid 在 氯化亚砜 作用下， 以 苯 为溶剂， 反应 1.0h， 以92%的产率得到6,8-diiodocoumarin-3-carbonyl chloride
  参考文献：
  名称：

  Synthesis and characterization of new diiodocoumarin derivatives with promising antimicrobial activities

  摘要：

  制备了一系列6,8-二碘香豆素-3-N-羧酰胺（4-11）。将乙酸乙酯的6,8-二碘香豆素-3-羧酸乙酯（1）与乙酰氰/ NH4OAc处理后，得到乙酸2-（3-羧酰胺-6,8-二碘香豆素-4-基）-2-乙腈酸乙酯（12）和2-氨基-4-羟基-7,9-二碘香豆酮[3,4-c]吡啶-1-碳腈（13），并在NH4OAc或甲胺的存在下用丙酮处理后，得到乙酸4-氧代-2,6-甲烷基-2-甲基-3,4,5,6-四氢-8,10-二碘苯并[2,1-g]-2H-1,3-噁唑啉-5-羧酸乙酯衍生物14a,b。所有化合物均评估了其抗微生物活性，化合物12-14a,b对所有测试的微生物均表现出明显的效果。

  DOI：

  10.3762/bjoc.7.199
• 作为产物：
  描述：

  ethyl 6,8-diiodo-2-oxo-2H-chromene-3-carboxylate 在 lithium hydroxide monohydrate 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 6,8-diiodocoumarin-3-carboxylic acid
  参考文献：
  名称：

  3-羰基，3-酰基和3-羧基肼基香豆素衍生物的合成和选择性人单胺氧化酶抑制作用

  摘要：

  几个-3-羰基（1 - 26），3-酰基（27 - 52），和3- carboxyhydrazido（53 - 58）香豆素已经以高收率（72-99％）合成并测试在体外对它们的人类单胺氧化酶A和B（hMAO-A和hMAO-B）的抑制活性。评价了香豆素核上的不同取代基对生物活性和同工型选择性的影响。对于使用IC 50获得高效且选择性的hMAO-B抑制剂而言，在3-乙酯香豆素环的C7位取代或在C3引入肼基取代基很重要。值在纳摩尔范围内。一些衍生物也进行了稳定性测试，在体外没有化​​学裂解。

  DOI：

  10.1016/j.ejmech.2011.07.017

文献信息

• Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives
  作者：Daniela Secci、Simone Carradori、Adriana Bolasco、Paola Chimenti、Matilde Yáñez、Francesco Ortuso、Stefano Alcaro

  DOI：10.1016/j.ejmech.2011.07.017

  日期：2011.10

  Several 3-carbonyl (1–26), 3-acyl (27–52), and 3-carboxyhydrazido (53–58) coumarins have been synthesized in high yields (72–99%) and tested in vitro for their human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitory activity. Different substituents on the coumarin nucleus were evaluated for their effect on biological activity and isoform selectivity. Substitution at position C7 of the 3-ethyl

  几个-3-羰基（1 - 26），3-酰基（27 - 52），和3- carboxyhydrazido（53 - 58）香豆素已经以高收率（72-99％）合成并测试在体外对它们的人类单胺氧化酶A和B（hMAO-A和hMAO-B）的抑制活性。评价了香豆素核上的不同取代基对生物活性和同工型选择性的影响。对于使用IC 50获得高效且选择性的hMAO-B抑制剂而言，在3-乙酯香豆素环的C7位取代或在C3引入肼基取代基很重要。值在纳摩尔范围内。一些衍生物也进行了稳定性测试，在体外没有化​​学裂解。
• Solid phase synthesis of substituted coumarin-3-carboxylic acids via the Knoevenagel condensation
  作者：Brett T Watson、Gerda E Christiansen

  DOI：10.1016/s0040-4039(98)01255-6

  日期：1998.8

  A solid phase synthesis of substituted coumarin-3-carboxylates using the Knoevenagel condensation reaction between ethyl malonate bound to the Wang resin and ortho-hydroxyarylaldehydes is described. The reaction has been shown to proceed cleanly to give the desired products.

  描述了使用结合在Wang树脂上的丙二酸乙酯和邻-羟基芳基醛之间的Knoevenagel缩合反应固相合成取代的香豆素-3-羧酸酯。已显示该反应可干净进行，得到所需产物。
• Benzopyran compound and use of the same
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0635504A1

  公开（公告）日：1995-01-25

  The invention is a 2H-1-benzopyran-2-on compound represented by the formula (1) : and a colorless ultraviolet absorber consisting of the compound, and a thermoplastic resin composition and formed article comprising said ultraviolet absorber, and can provide a thermoplastic resin composition and a formed article of the composition which have excellent heat stability and sublimation resistance, comprise a non-coloring ultraviolet absorber, and are excellent in ultraviolet barrier property.

  本发明是一种由式（1）表示的 2H-1-苯并吡喃-2-酮化合物： 和由该化合物组成的无色紫外线吸收剂，以及包含所述紫外线吸收剂的热塑性树脂组合物和成型品，可提供热稳定性和抗升华性优异、包含无色紫外线吸收剂、紫外线阻隔性优异的热塑性树脂组合物和由该组合物制成的成型品。
• Synthesis of Coumarin-3-O-acylisoureas by Different Carbodiimides
  作者：Leonardo Bonsignore、Filippo Cottiglia、Silvio M. Lavagna、Giuseppe Loy、Daniela Secci

  DOI：10.3987/com-98-s(h)18

  日期：——

  The synthesis and isolation of some O-acylisourea derivatives are described. The reaction between coumarin-3-carboxylic acids and diisopropyl- and di-tert-butyl-carbodiimides leads only to coumarin-isourea derivatives except for two reactions which lead, as by-products, also to coumarin-urea derivatives.
• Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-d-aspartate receptors
  作者：Mark W. Irvine、Blaise M. Costa、Arturas Volianskis、Guangyu Fang、Laura Ceolin、Graham L. Collingridge、Daniel T. Monaghan、David E. Jane

  DOI：10.1016/j.neuint.2011.12.020

  日期：2012.9

  N-Methyl-D-aspartate receptors (NMDARs) are known to be involved in a range of neurological and neurodegenerative disorders and consequently the development of compounds that modulate the function of these receptors has been the subject of intense interest. We have recently reported that 6-bromocoumarin-3-carboxylic acid (UBP608) is a negative allosteric modulator with weak selectivity for GluN2A-containing NMDARs. In the present study, a series of commercially available and newly synthesized coumarin derivatives have been evaluated in a structure-activity relationship (SAR) study as modulators of recombinant NMDAR activity. The main conclusions from this SAR study were that substituents as large as iodo were accommodated at the 6-position and that 6,8-dibromo or 6,8-diiodo substitution of the coumarin ring enhanced the inhibitory activity at NMDARs. These coumarin derivatives are therefore excellent starting points for the development of more potent and GluN2 subunit selective inhibitors, which may have application in the treatment of a range of neurological disorders such as neuropathic pain, epilepsy and depression. Surprisingly, 4-methyl substitution of UBP608 to give UBP714, led to conversion of the inhibitory activity of UBP608 into potentiating activity at recombinant GluN1/GluN2 receptors. UBP714 also enhanced NMDAR mediated field EPSPs in the CA1 region of the hippocampus. UBP714 is therefore a novel template for the development of potent and subunit selective NMDAR potentiators that may have therapeutic applicability in the treatment of patients with cognitive deficits or schizophrenia. (C) 2012 Elsevier Ltd. All rights reserved.